Extract
People with interstitial lung disease (ILD) experience dyspnoea on exertion, poor exercise capacity and reduced health-related quality of life. Whilst new pharmaceutical treatments slow disease progression in some patients, most care options remain supportive [1, 2]. Pulmonary rehabilitation (PR) is recommended for people with ILD, however not all participants have a positive response [3–5]. A recent randomised controlled trial found that the benefits of exercise training were greatest in individuals who were able to progress their exercise training loads according to the study protocol [4]. The aim of this analysis was to identify predictors of the ability to adhere to the exercise progression protocol in people with ILD.
Abstract
In ILD, adherence to the training sessions in pulmonary rehabilitation predicts progression of exercise training loads; declining lung function is an independent predictor of failure to progress training loads http://bit.ly/2Z4x9Nw
Footnotes
This trial is registered at www.anzctr.org.au with identifier number ACTRN12611000416998. De-identified participant data are available from the authors on reasonable request, with oversight of the relevant human research ethics committee.
Support statement: No specific grant from funding agencies in the public, commercial or not-for-profit sectors was received for this research. L.M. Dowman received a National Health and Medical Research Council postgraduate scholarship (grant ID: GNT1017802); and the randomised controlled trial received grant funding from the Pulmonary Fibrosis Foundation/American Thoracic Society Foundation, Institute for Breathing and Sleep and Eirene Lucas Foundation. These funding agencies had no role in the management of this study. Other authors have no disclosures of funding. Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: A. Nakazawa has nothing to disclose.
Conflict of interest: L.M. Dowman has nothing to disclose.
Conflict of interest: N.S. Cox has nothing to disclose.
Conflict of interest: C.F. McDonald reports speaker fees from GSK, advisory board fees from Pfizer and Novartis, and speaker fees paid to her hospital from Menarini, outside the submitted work.
Conflict of interest: C.J. Hill has nothing to disclose.
Conflict of interest: A. Lee has nothing to disclose.
Conflict of interest: A.E. holland has nothing to disclose.
- Received December 12, 2018.
- Accepted August 3, 2019.
- Copyright ©ERS 2019
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.